Aarey Drugs & Pharmaceuticals (BOM:524412) Moat Score: 0/10 (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524412 Aarey Drugs & Pharmaceuticals Ltd BOM:524412
60 GF Score
Price ₹78.39
GF Value ₹58.31
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Aarey Drugs & Pharmaceuticals Moat Score?

Aarey Drugs & Pharmaceuticals has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Aarey Drugs & Pharmaceuticals has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Aarey Drugs & Pharmaceuticals might have No Moat - No discernible moat.

Aarey Drugs & Pharmaceuticals  (BOM:524412) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Aarey Drugs & Pharmaceuticals Moat Score Related Terms

BOM:524412
60GF Score
Aarey Drugs & Pharmaceuticals Ltd BOM:524412
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Aarey Drugs & Pharmaceuticals (BOM:524412) Overvalued in 2026?

Based on GuruFocus' analysis, Aarey Drugs & Pharmaceuticals stock appears to be overvalued. The current stock price of ₹78.39 is trading 34.4% above its estimated GF Value™ of ₹58.31. GuruFocus considers Aarey Drugs & Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for BOM:524412:

  • Moat Score: 0
  • GF Value™: ₹58.31 vs. price of ₹78.39 (34.4% above fair value)
  • GF Score™: 60/100 with 2 warning signs

No single metric tells the full story. See the BOM:524412 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aarey Drugs & Pharmaceuticals Business Description

Other Exchanges AAREYDRUGS:India
Address 340/348, Narshi Natha Street, 107, Sahakar Bhavan, Masjid Bunder, Mumbai, MH, IND, 400 009
Aarey Drugs & Pharmaceuticals Ltd is engaged in bulk drug manufacturing and offers products for industrial applications. The company manufactures active pharmaceutical ingredients, intermediates, and specialty chemicals. It is also involved in the trading of industrial solvents and chemicals. The products offered by the company include N-Methyl urea, Dimethyl urea, Mefenamic acid, Metformin, Doxaphylline, and BMD among others. The company principally carries out its business operations in India.
60GF Score

Get the complete analysis for BOM:524412

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹78.39
Price
₹58.31
GF Value